Answers are grounded in this paper and cite their sources.
Pyruvate kinase M2 (PKM2) is a glycolytic enzyme that also exerts non-metabolic functions in transcriptional regulation and represents an emerging pharmacological target in inflammation-related disorders. Emerging evidence indicates that altered PKM2 expression, conformational switching and nuclear translocation contribute to the pathogenesis of autoimmune diseases, including rheumatoid arthritis, inflammatory bowel disease, type 1 diabetes and its complications, systemic sclerosis, psoriasis, systemic lupus erythematosus and multiple sclerosis. In the cytoplasm, PKM2 regulates glycolytic flux and supports the metabolic demands of activated immune cells and disease-relevant parenchymal or fibroblast-like cells. Under inflammatory, hypoxic or growth factor-related stimulation, dimeric PKM2 translocates into the nucleus and cooperates with HIF-1α, STAT3, β-catenin and BCL6 to amplify inflammatory, fibrotic and tissue-remodeling programs. Pharmacological strategies that modulate PKM2, particularly by promoting tetramerization, altering enzymatic activity or limiting nuclear translocation, have shown therapeutic potential in preclinical models. However, PKM2 functions differ across cell types and disease contexts, including protective roles in epithelial repair and diabetic nephropathy. Therefore, PKM2-targeted strategies should move beyond global inhibition toward selective and context-dependent modulation of conformation, enzymatic activity and nuclear trafficking. Defining these divergent functions may provide a mechanistic and pharmacological basis for more selective immunometabolic therapies in autoimmune diseases.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: